JP2004501161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501161A5 JP2004501161A5 JP2002504283A JP2002504283A JP2004501161A5 JP 2004501161 A5 JP2004501161 A5 JP 2004501161A5 JP 2002504283 A JP2002504283 A JP 2002504283A JP 2002504283 A JP2002504283 A JP 2002504283A JP 2004501161 A5 JP2004501161 A5 JP 2004501161A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- glycopeptide
- hydrogen
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical group NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 36
- 102000002068 Glycopeptides Human genes 0.000 description 36
- 108010015899 Glycopeptides Proteins 0.000 description 36
- 229910052739 hydrogen Inorganic materials 0.000 description 23
- 239000001257 hydrogen Substances 0.000 description 23
- 125000000392 cycloalkenyl group Chemical group 0.000 description 18
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 150000001720 carbohydrates Chemical group 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- 125000005017 substituted alkenyl group Chemical group 0.000 description 12
- 125000000547 substituted alkyl group Chemical group 0.000 description 12
- 125000004426 substituted alkynyl group Chemical group 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 9
- -1 N- (phosphonomethyl) aminomethyl Chemical group 0.000 description 7
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21341000P | 2000-06-22 | 2000-06-22 | |
| PCT/US2001/013998 WO2001098328A2 (en) | 2000-06-22 | 2001-05-01 | Glycopeptide phosphonate derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006304562A Division JP2007045842A (ja) | 2000-06-22 | 2006-11-09 | グリコペプチドホスホネート誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004501161A JP2004501161A (ja) | 2004-01-15 |
| JP2004501161A5 true JP2004501161A5 (https=) | 2006-05-25 |
| JP3900491B2 JP3900491B2 (ja) | 2007-04-04 |
Family
ID=22795013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504283A Expired - Fee Related JP3900491B2 (ja) | 2000-06-22 | 2001-05-01 | グリコペプチドホスホネート誘導体 |
| JP2006304562A Pending JP2007045842A (ja) | 2000-06-22 | 2006-11-09 | グリコペプチドホスホネート誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006304562A Pending JP2007045842A (ja) | 2000-06-22 | 2006-11-09 | グリコペプチドホスホネート誘導体 |
Country Status (36)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1140993E (pt) * | 1998-12-23 | 2003-10-31 | Theravance Inc | Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos |
| CA2726789A1 (en) | 2000-02-05 | 2001-11-08 | Theravance, Inc. | Cyclodextrin containing glycopeptide antibiotic compositions |
| AU2001259298A1 (en) | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Polyacid glycopeptide derivatives |
| WO2001098329A1 (en) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
| ES2302733T3 (es) | 2000-06-22 | 2008-08-01 | Theravance, Inc. | Derivados carboxi-sacaridos de glucopeptido. |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| US6872804B2 (en) | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
| TWI312785B (en) * | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
| TWI233932B (en) | 2001-08-24 | 2005-06-11 | Theravance Inc | Process for purifying glycopeptide phosphonate derivatives |
| TWI275594B (en) * | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
| TWI325323B (en) * | 2002-05-24 | 2010-06-01 | Theravance Inc | Cross-linked glycopeptide-cephalosporin antibiotics |
| AU2003243574A1 (en) | 2002-06-17 | 2003-12-31 | Theravance, Inc. | PROCESS FOR PREPARING N-PROTECTED Beta-AMINO ALDEHYDE COMPOUNDS |
| JP2006528704A (ja) * | 2003-05-27 | 2006-12-21 | セラヴァンス インコーポレーテッド | グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用 |
| DE602004010915T2 (de) * | 2003-07-22 | 2008-12-11 | Theravance, Inc., South San Francisco | Verwendung eines antimykotischen echinocandin-mittels in kombination mit einem antibakteriellen glycopeptid-mittel |
| TWI342312B (en) * | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
| CN101395164A (zh) * | 2006-01-10 | 2009-03-25 | 罗伊·J·于 | N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法 |
| JP2008112847A (ja) * | 2006-10-30 | 2008-05-15 | Shin Etsu Chem Co Ltd | 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池 |
| WO2008077241A1 (en) | 2006-12-22 | 2008-07-03 | Targanta Therapeutics, Inc. | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections |
| US20090069219A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched telavancin |
| WO2009061208A1 (en) * | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| CA2710602A1 (en) * | 2007-12-26 | 2009-07-09 | Lead Therapeutics, Inc. | Novel semi-synthetic glycopeptides as antibacterial agents |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| WO2010048340A2 (en) * | 2008-10-24 | 2010-04-29 | Lead Therapeutics, Inc. | Novel semi-synthetic glycopeptides as antibacterial agents |
| GB2465863A (en) * | 2008-12-05 | 2010-06-09 | Lead Therapeutics Inc | Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections |
| US9682061B2 (en) | 2009-04-28 | 2017-06-20 | The Medicines Company | Methods of treating bacterial infections using oritavancin |
| BRPI1015120B8 (pt) | 2009-05-08 | 2022-02-15 | Basf As | Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico |
| US20110009596A1 (en) * | 2009-07-09 | 2011-01-13 | Plus Chemicals Sa | Process for the preparation of n-protected-decylaminoethanal |
| ES2618604T3 (es) | 2010-11-05 | 2017-06-21 | Pronova Biopharma Norge As | Métodos de tratamiento usando compuestos lipídicos |
| WO2013034676A1 (en) | 2011-09-09 | 2013-03-14 | Sandoz Ag | Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin |
| WO2013034675A1 (en) | 2011-09-09 | 2013-03-14 | Sandoz Ag | Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof |
| JP5724937B2 (ja) * | 2012-04-23 | 2015-05-27 | ニプロ株式会社 | 腎臓集積性を示すペプチド、製剤 |
| CN103897040B (zh) * | 2012-12-27 | 2018-05-22 | 浙江医药股份有限公司新昌制药厂 | 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途 |
| MX377728B (es) | 2013-02-28 | 2025-03-11 | Pronova Biopharma Norge As | Composición que comprende un compuesto lípido, un triglicerido y un tensioactivo, y métodos de uso de la misma. |
| KR102237887B1 (ko) | 2013-03-15 | 2021-04-07 | 멜린타 서브시디어리 코프. | 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법 |
| CN105085636B (zh) * | 2014-05-19 | 2020-05-01 | 中国医学科学院药物研究所 | 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用 |
| KR20170123650A (ko) | 2015-02-23 | 2017-11-08 | 세라밴스 바이오파마 안티바이오틱스 아이피, 엘엘씨 | 텔라반신을 투여하는 투여량 및 방법 |
| ES2980790T3 (es) | 2015-04-28 | 2024-10-03 | Basf As | Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| CN106188243B (zh) * | 2015-05-05 | 2020-06-26 | 博瑞生物医药（苏州）股份有限公司 | 一种奥利万星的制备方法 |
| US20200171124A1 (en) | 2016-04-15 | 2020-06-04 | Lupin Limited | Topical compositions for ophthalmic and otic use |
| KR20190005940A (ko) * | 2016-05-09 | 2019-01-16 | 셀리아 파마슈티칼즈 에이피에스 | 안정화된 글리코펩티드 항생제 제형 |
| IL270685B (en) | 2017-05-22 | 2022-09-01 | Insmed Inc | Cleavable derivatives of lipoglycopeptide and their uses |
| CN107629116B (zh) * | 2017-09-08 | 2021-05-07 | 福建省微生物研究所 | 一种特拉万星的纯化方法 |
| CN107629115B (zh) * | 2017-09-08 | 2021-05-07 | 福建省微生物研究所 | 一种特拉万星的纯化方法 |
| CN107987131B (zh) * | 2017-11-16 | 2021-03-09 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的化合物、其制备方法和应用 |
| IL308604B2 (en) | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| CN108409837B (zh) * | 2018-03-06 | 2021-09-24 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用 |
| JP2022507357A (ja) * | 2018-11-21 | 2022-01-18 | インスメッド インコーポレイテッド | リポグリコペプチドクリーバブル誘導体およびそれらの使用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6872A (en) * | 1849-11-13 | Means of changing the combination in bevolving tumbler-locks | ||
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| US4639433A (en) * | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| US4885275A (en) * | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| ZA909847B (en) | 1989-12-13 | 1992-08-26 | Lilly Co Eli | Glycopeptide derivatives |
| US5750509A (en) | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
| US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| EP0674528A4 (en) | 1992-12-02 | 1996-06-26 | Insite Vision Inc | DRUG DELIVERY SYSTEM BASED ON CYCLODEXTRIN AND A POLYMER. |
| US6077822A (en) * | 1993-09-14 | 2000-06-20 | Dumex-Alpharma A/S | Drug salts |
| TW457248B (en) * | 1994-01-28 | 2001-10-01 | Lilly Co Eli | Glycopeptide antibiotic derivatives |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| US5614615A (en) * | 1995-03-21 | 1997-03-25 | The Scripps Research Institute | Sialyl Lewis X mimetics incorporating fucopeptides |
| US5919756A (en) | 1996-06-28 | 1999-07-06 | Eli Lilly And Company | Amides |
| US5916873A (en) | 1997-04-17 | 1999-06-29 | Eli Lilly And Company | Teicoplanin derivatives |
| EP1025852A4 (en) * | 1997-10-03 | 2001-11-07 | Fujisawa Pharmaceutical Co | VANCOMYCIN ANTIBIOTIC HYDROCHLORIDES AND METHOD FOR THE PRODUCTION THEREOF |
| US6323176B1 (en) * | 1998-02-25 | 2001-11-27 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| CA2337103A1 (en) | 1998-07-14 | 2000-01-27 | Robert Kerns | Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same |
| PT1140993E (pt) * | 1998-12-23 | 2003-10-31 | Theravance Inc | Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos |
| DE19911097A1 (de) | 1999-03-12 | 2000-09-14 | Basf Ag | Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen |
| US6518243B1 (en) | 1999-04-02 | 2003-02-11 | Trustees Of Princeton University | Desleucyl glycopeptide antibiotics and methods of making same |
| JP2000302687A (ja) | 1999-04-22 | 2000-10-31 | Sagami Chem Res Center | 抗菌性オリゴマー及び抗菌剤 |
| CA2726789A1 (en) | 2000-02-05 | 2001-11-08 | Theravance, Inc. | Cyclodextrin containing glycopeptide antibiotic compositions |
| AU2001259298A1 (en) | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Polyacid glycopeptide derivatives |
| PL218223B1 (pl) | 2000-06-21 | 2014-10-31 | Cubist Pharmaceuticals | Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny |
| ES2302733T3 (es) | 2000-06-22 | 2008-08-01 | Theravance, Inc. | Derivados carboxi-sacaridos de glucopeptido. |
| WO2001098326A2 (en) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
| WO2001098329A1 (en) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| TWI275594B (en) * | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
| TWI233932B (en) * | 2001-08-24 | 2005-06-11 | Theravance Inc | Process for purifying glycopeptide phosphonate derivatives |
-
2001
- 2001-01-05 UA UA2003010499A patent/UA75083C2/uk unknown
- 2001-04-27 MY MYPI20012000 patent/MY127081A/en unknown
- 2001-04-29 EG EG2001040429A patent/EG26726A/en active
- 2001-04-30 AR ARP010102060A patent/AR035333A1/es active IP Right Grant
- 2001-05-01 CZ CZ20023942A patent/CZ303672B6/cs not_active IP Right Cessation
- 2001-05-01 AU AU2001261107A patent/AU2001261107B2/en not_active Expired
- 2001-05-01 EP EP01934967A patent/EP1292612B1/en not_active Expired - Lifetime
- 2001-05-01 RS YUP-969/02A patent/RS50499B/sr unknown
- 2001-05-01 CA CA2411590A patent/CA2411590C/en not_active Expired - Lifetime
- 2001-05-01 WO PCT/US2001/013998 patent/WO2001098328A2/en not_active Ceased
- 2001-05-01 JP JP2002504283A patent/JP3900491B2/ja not_active Expired - Fee Related
- 2001-05-01 PT PT01934967T patent/PT1292612E/pt unknown
- 2001-05-01 US US09/847,042 patent/US6635618B2/en not_active Expired - Lifetime
- 2001-05-01 HK HK03104490.4A patent/HK1052191B/en not_active IP Right Cessation
- 2001-05-01 AT AT01934967T patent/ATE337334T1/de active
- 2001-05-01 IL IL152408A patent/IL152408A/en unknown
- 2001-05-01 KR KR1020027017472A patent/KR100768488B1/ko not_active Expired - Lifetime
- 2001-05-01 CN CNB018113508A patent/CN100469788C/zh not_active Expired - Lifetime
- 2001-05-01 MX MXPA02012745A patent/MXPA02012745A/es active IP Right Grant
- 2001-05-01 DK DK01934967T patent/DK1292612T3/da active
- 2001-05-01 CA CA2713965A patent/CA2713965A1/en not_active Abandoned
- 2001-05-01 HU HU0301320A patent/HU229370B1/hu not_active IP Right Cessation
- 2001-05-01 SI SI200130642T patent/SI1292612T1/sl unknown
- 2001-05-01 BR BRPI0111222A patent/BRPI0111222B8/pt not_active IP Right Cessation
- 2001-05-01 NZ NZ522279A patent/NZ522279A/en not_active IP Right Cessation
- 2001-05-01 SK SK1852-2002A patent/SK287470B6/sk not_active IP Right Cessation
- 2001-05-01 EA EA200300050A patent/EA005953B1/ru not_active IP Right Cessation
- 2001-05-01 DE DE60122516T patent/DE60122516T2/de not_active Expired - Lifetime
- 2001-05-01 ES ES01934967T patent/ES2271012T3/es not_active Expired - Lifetime
- 2001-05-01 HR HR20020888A patent/HRP20020888B1/xx not_active IP Right Cessation
- 2001-05-01 AU AU6110701A patent/AU6110701A/xx active Pending
- 2001-05-01 PL PL359419A patent/PL207101B1/pl unknown
- 2001-05-01 TW TW090110397A patent/TWI305209B/zh not_active IP Right Cessation
-
2002
- 2002-10-29 IS IS6600A patent/IS2303B/is unknown
- 2002-11-19 ZA ZA200209419A patent/ZA200209419B/en unknown
- 2002-12-11 NO NO20025954A patent/NO330360B1/no not_active IP Right Cessation
-
2003
- 2003-05-12 US US10/436,341 patent/US6872701B2/en not_active Expired - Lifetime
- 2003-09-24 US US10/669,778 patent/US6887976B2/en not_active Expired - Lifetime
-
2005
- 2005-01-18 US US11/037,934 patent/US7008923B2/en not_active Expired - Lifetime
- 2005-11-02 US US11/265,570 patent/US7208471B2/en not_active Expired - Lifetime
-
2006
- 2006-09-04 CY CY20061101256T patent/CY1105194T1/el unknown
- 2006-10-23 US US11/584,908 patent/US7351691B2/en not_active Expired - Lifetime
- 2006-11-09 JP JP2006304562A patent/JP2007045842A/ja active Pending
-
2007
- 2007-10-24 US US11/977,429 patent/US7700550B2/en not_active Expired - Fee Related
-
2010
- 2010-03-02 US US12/715,554 patent/US8101575B2/en not_active Expired - Fee Related
-
2011
- 2011-11-18 NO NO2011025C patent/NO2011025I1/no not_active IP Right Cessation
- 2011-11-30 DE DE201112100062 patent/DE122011100062I1/de active Pending
- 2011-11-30 LU LU91908C patent/LU91908I2/fr unknown
- 2011-12-16 US US13/328,284 patent/US8541375B2/en not_active Expired - Fee Related
-
2012
- 2012-02-02 CY CY2012006C patent/CY2012006I1/el unknown
-
2013
- 2013-07-17 US US13/944,193 patent/US8859506B2/en not_active Expired - Fee Related
-
2014
- 2014-04-15 HU HUS1400024C patent/HUS1400024I1/hu unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004501161A5 (https=) | ||
| CA2411590A1 (en) | Glycopeptide phosphonate derivatives | |
| US10111891B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| US9782421B1 (en) | Neridronic acid molecular complex for treating complex regional pain syndrome | |
| US10111837B2 (en) | Dosage forms for oral administration of zoledronic acid or related compounds | |
| US10173986B2 (en) | Methods for the safe administration of imidazole or imidazolium compounds | |
| US9999628B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
| US9877977B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| US10028969B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| US10039774B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
| US9655908B2 (en) | Neridronic acid molecular complex for treating complex regional pain syndrome | |
| US20180050053A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| JP2020063241A5 (https=) | ||
| US20180133232A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| JP2022528851A5 (https=) | ||
| US20180228820A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| JP2023512501A5 (https=) | ||
| US20170079998A1 (en) | Osteoclast inhibitors for knee conditions | |
| US20180055767A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
| JP3705360B2 (ja) | 骨量低下疾患治療剤 | |
| US10350227B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
| US20190030052A1 (en) | Neridronic acid for treating complex regional pain syndrome | |
| JP2009504783A5 (https=) | ||
| CN1396830A (zh) | 含有双膦酸盐的肠胃外药物组合物 | |
| JP2009526755A (ja) | Ｎ−（ホスホノアルキル）−アミノ酸、その誘導体及び組成物及びその利用法 |